Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 5/20 | 0.48 |
| ▸ | MAOB | P27338 | 9/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28559850 | 0.90 | MAOB (0.43) | ABCB1MAOBPTPN1ENPP2HTR1A | |
| SCHEMBL6810250 | 0.88 | MAOB (0.55) | ABCB1MAOBHTR1ADRD2 | |
| SCHEMBL2451926 | 0.85 | APP (0.49) | ABCB1MAOBAPPHTR1A | |
| SCHEMBL10830875 | 0.80 | TACR1 (0.41) | MAOB | |
| SCHEMBL2095414 | 0.78 | ALDH1A1 (0.42) | ABCB1TSHRMAPK1 | |
| SCHEMBL95381 | 0.77 | TSHR (0.44) | MAOBTSHRMAPK1HTR1ADRD2 | |
| SCHEMBL5672700 | 0.77 | IDO1 (0.41) | MAOB | |
| SCHEMBL5544217 | 0.76 | APLNR (0.46) | ABCB1TSHRMAPK1 | |
| SCHEMBL28559844 | 0.76 | MAOB (0.36) | ABCB1MAOBTSHRMAPK1 | |
| SCHEMBL15389735 | 0.76 | LOXL2 (0.50) | ABCB1MAOBENPP2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242662-A1 | Organic Compounds | NIHONYANAGI ATSUKO | 2008-10-02 | — | — | US | claimed |
| EP-1915366-A2 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | Novartis AG (CH) | 2008-04-30 | — | — | EP | claimed |
| WO-2006128659-A2 | PIPERAZINE DERIVATIVE RENIN INHIBITORS. | NOVARTIS AG (CH) | 2006-12-07 | — | — | WO | claimed |
| US-20060094715-A1 | 5-Ht4 receptor antagonists for the treatment of heart failure | SERODUS AS (NO) | 2006-05-04 | — | — | US | claimed |
| US-20080242662-A1 | Organic Compounds | NIHONYANAGI ATSUKO | 2008-10-02 | — | — | US | disclosed |
| EP-1915366-A2 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | Novartis AG (CH) | 2008-04-30 | — | — | EP | disclosed |
| WO-2006128659-A2 | PIPERAZINE DERIVATIVE RENIN INHIBITORS. | NOVARTIS AG (CH) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242662-A1 | Organic Compounds | REN, ACE, ECE1 | ABCB1 266/4885MAOB 40/4885PTPN1 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.